Britain Approves GSK-Vir Antibody-Based COVID-19 Treatment

Britain’s drug regulator on Thursday approved GSK and Vir Biotechnology’s antibody based COVID-19 treatment, Xevudy, for people with mild-to-moderate COVID-19 who are at high risk of developing severe disease. Read More